Toronto -
StageZero's Chairman and CEO,
Analyst and Investor Call
Event Date:
Time:
Webcast Link: https://www.gowebcasting.com/12565
Conference Call Numbers
International Toll: +1-604-638-5340
About
The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in
Aristotle, as well as additional cancer diagnostics (ColonSentry, BreastSentry, and the Prostate Health Index) are processed at the Company's clinical laboratory,
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as 'expects', 'will' and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Contact:
Tel: 1-855-420-7140
Email: rgreco@stagezerols.com
(C) 2023 Electronic News Publishing, source